Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Invest Ophthalmol Vis Sci. 2011 Feb 25;52(2):1087-92. doi: 10.1167/iovs.09-4170.
To evaluate the role of umbilical cord serum therapy in cases of acute ocular chemical burns.
In a double-blind prospective randomized controlled clinical study, 33 eyes of 32 patients with acute ocular chemical burns of grade III, IV, and V severity were randomized into three groups: umbilical cord serum (n = 12), autologous serum (n = 11), and artificial tears (0.5% HPMC+0.3% glycerin; n = 10). In addition, all eyes received standard medical therapy. The parameters evaluated were pain score, size, and area of epithelial defect, extent of limbal ischemia, corneal clarity, and symblepharon formation. The patients were followed up at day 1, 3, 7, 14, and 21 and at the end of months 1, 2, and 3.
Mean time to complete epithelialization was 21.16 ± 26.81, 56.6 ± 35.5, and 40.13 ± 35.79 days in cord serum, autologous serum, and artificial tears groups respectively (P = 0.02). By day 21, the mean percentage decrease in epithelial defect diameter was 94.63 ± 11.99 with cord serum compared with 53.17 ± 34.81 and 64.22 ± 42.43 with autologous serum and artificial tears, respectively (P = 0.01). By month 3, the extent of limbal ischemia with cord serum showed a mean percentage decrease of 73.43 ± 25.51 compared with 35.64 ± 25.60 and 43.71 ± 28.71 with autologous serum and artificial tears, respectively (P = 0.008). More patients had clear corneas with cord serum compared with autologous serum and artificial tears (P = 0.048). No significant difference was seen between the groups with regard to symblepharon formation (P = 0.07).
Umbilical cord serum therapy is more effective than autologous serum eye drops or artificial tears in ocular surface restoration after acute chemical injuries. (www.controlled-trials.com number, ISRCTN08131903.).
评估脐带血清疗法在急性眼部化学灼伤病例中的作用。
在一项双盲前瞻性随机对照临床试验中,将 32 例 III、IV 和 V 级重度急性眼部化学灼伤患者的 33 只眼随机分为三组:脐带血清组(n = 12)、自体血清组(n = 11)和人工泪液组(0.5% HPMC+0.3%甘油;n = 10)。此外,所有患者均接受标准药物治疗。评估的参数包括疼痛评分、上皮缺损大小和面积、角膜缘缺血程度、角膜清晰度和睑球粘连形成。患者在第 1、3、7、14 和 21 天以及第 1、2 和 3 个月时进行随访。
脐带血清组、自体血清组和人工泪液组完全上皮化的平均时间分别为 21.16 ± 26.81、56.6 ± 35.5 和 40.13 ± 35.79 天(P = 0.02)。第 21 天,脐带血清组上皮缺损直径的平均百分比减少率为 94.63 ± 11.99%,而自体血清组和人工泪液组分别为 53.17 ± 34.81%和 64.22 ± 42.43%(P = 0.01)。第 3 个月时,脐带血清组角膜缘缺血程度的平均百分比减少率为 73.43 ± 25.51%,而自体血清组和人工泪液组分别为 35.64 ± 25.60%和 43.71 ± 28.71%(P = 0.008)。与自体血清组和人工泪液组相比,更多患者使用脐带血清后角膜清晰(P = 0.048)。在睑球粘连形成方面,三组间无显著差异(P = 0.07)。
与自体血清滴眼液或人工泪液相比,脐带血清疗法在急性化学伤后眼表修复方面更有效。(www.controlled-trials.com 注册号,ISRCTN08131903.)